^
CANCER:

Esophageal Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
PD-1 expression + CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Esophageal Cancer
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Esophageal Cancer
pembrolizumab
Sensitive
:
C1
No biomarker
Esophageal Squamous Cell Carcinoma
tislelizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
C1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
sintilimab
Sensitive
:
A1
MSI-H/dMMR
Esophageal Cancer
dostarlimab
Sensitive
:
C1
No biomarker
Esophageal Cancer
XP
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive
:
A2
No biomarker
Esophageal Cancer
docetaxel + irinotecan
Sensitive
:
A2
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
C1
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
C1
No biomarker
Esophageal Cancer
5-fluorouracil + irinotecan
Sensitive
:
A2
No biomarker
Esophageal Cancer
irinotecan
Sensitive
:
A2
No biomarker
Esophageal Cancer
CaT
Sensitive
:
A2
No biomarker
Esophageal Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
docetaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
IP
Sensitive
:
A2
No biomarker
Esophageal Cancer
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Esophageal Cancer
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive
:
A2
NTRK3 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
C1
NTRK3 fusion
Esophageal Cancer
entrectinib
Sensitive
:
C1
NTRK2 fusion
Esophageal Cancer
entrectinib
Sensitive
:
C1